The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.
 
Hitomi Sumiyoshi Okuma
No Relationships to Disclose
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Chikashi Ishioka
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Incyte Japan; Kyowa Kirin International; Lilly Japan; M3; M3; Merck; MSD; Nihon Servier; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Ascent Pharmahealth (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Hitachi (Inst); Incyte (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka; Riken Genesis (Inst); Taiho Pharmaceutical (Inst); Tsumura & Co. (Inst)
 
Eishi Baba
Honoraria - Chugai Pharma; Daiichi Sankyo; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Ichiro Kinoshita
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Chugai Pharma; MSD; Takeda
 
Manabu Muto
Speakers' Bureau - Canon Medical System; Chugai Pharma; Daiichi Sankyo/Lilly; Illumina; Incyte Japan; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Shionogi
Research Funding - Canon Medical System; Chugai Pharma; H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical
 
Marcelo Severino Bulauitan Imasa
Consulting or Advisory Role - AstraZeneca; Pfizer
Speakers' Bureau - AstraZeneca; MSD; Pfizer; Roche; Sandoz
Research Funding - MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
PEI JYE VOON
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Janssen-Cilag (Inst); Johnson & Johnson (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); ROCHE (Inst); Viracta Therapeutics (Inst)
 
Kathleen Yasmin de Almeida
No Relationships to Disclose
 
Hwoei Fen Soo Hoo
No Relationships to Disclose
 
Masahiko Ichimura
No Relationships to Disclose
 
Chiharu Mizoguchi
No Relationships to Disclose
 
Wataru Munakata
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Eisai; Genmab; Gilead Sciences; Janssen; Nippon Kayaku; Nippon Shinyaku; Novartis Pharmaceuticals UK Ltd.; ONO PHARMACEUTICAL; SymBio Pharmaceuticals; Takeda
Research Funding - Chugai Pharma (Inst); Genmab (Inst); Janssen (Inst); Kyowa Kirin (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Takeda (Inst)
 
Shinji Kohsaka
No Relationships to Disclose
 
Taro Shibata
No Relationships to Disclose
 
Yasushi Yatabe
Research Funding - Agilent (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Kenichi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; IQvia; Lilly; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroyuki Mano
Employment - CureGene; CureGene (I)
Leadership - CureGene
Research Funding - Ambry Genetics; Daiichi Sankyo; Konica Minolta; Ono Pharmaceutical; Ono Pharmaceutical; PFDeNA
Patents, Royalties, Other Intellectual Property - Probe design for gene fusion detection (Inst)
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)